Indeed, a constitutive activation of the AKT pathway and the phosphorylation of its targets such as mTOR, p70S6K, and 4E-BP1 are detected in about 60% of AML patients [7,8,9], and are mostly described as connected with a poorer prognosis [10,11,12,13,14]. This evidence concerns the gene AKT1 and acute myeloid leukemia.